 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"PHENYTOIN"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such [0m
[31mas Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry.[0m
[31mThis can be done by calling the toll free number [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. Information on the registry can also be found at the website [0m
[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal [0m
[31mphenytoin exposure is associated with an increased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. PHENYTOIN: pregnancy: In addition, the fetal hydantoin syndrome a [0m
[31mpattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among [0m
[31mchildren born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including [0m
[31mneuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other [0m
[31mmanifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general [0m
[31mpopulation, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. PHENYTOIN: pregnancy: The background [0m
[31mrisk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during [0m
[31mpregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment[0m
[31mof dosage [0m[31m . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased [0m
[31mlevels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before [0m
[31mdelivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately [0m[1;31m2[0m[31m. PHENYTOIN: pregnancy: [0m[1;31m4[0m[31m-fold [0m
[31mincreased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been [0m
[31mreported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental [0m
[31mdeficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth [0m
[31mretardation. Malformations [0m[1;31m([0m[31mincluding craniofacial, cardiovascular, neural, limb, and digit abnormalities[0m[1;31m)[0m[31m were observed in rats, rabbits, and mice at doses as low as [0m[1;31m100[0m[31m, [0m[1;31m75[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg, [0m
[31mrespectively.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: use_in_specific_populations: Information on the registry can also be found at the website [0m[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . Risk Summary In humans, prenatal exposure to [0m
[31mphenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal phenytoin exposure is associated with an increased incidence of major malformations [0m
[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. In addition, the fetal hydantoin syndrome a pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth[0m
[31mabnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during[0m
[31mpregnancy [0m[31m . There have been several reported cases of malignancies, including neuroblastoma, in children whose mothers received phenytoin during pregnancy. PHENYTOIN: use_in_specific_populations: [0m
[31mAdministration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other manifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth [0m
[31mimpairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in [0m
[31mclinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations [0m
[31mDisease-associated maternal risk An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may [0m
[31mbe valuable in the management of pregnant women as a guide to appropriate adjustment of dosage [0m[31m . However, postpartum restoration of the original dosage will probably be indicated. PHENYTOIN: [0m
[31muse_in_specific_populations: Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns[0m
[31mexposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. Data Human Data Meta-analyses [0m
[31musing data from published observational studies and registries have estimated an approximately [0m[1;31m2.4[0m[31m-fold increased risk for any major malformation in children with prenatal phenytoin exposure compared [0m
[31mto controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial [0m
[31manomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental deficiencies. PHENYTOIN: use_in_specific_populations: Animal Data Administration of phenytoin to [0m
[31mpregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth retardation. Malformations [0m[1;31m([0m[31mincluding craniofacial, cardiovascular,[0m
[31mneural, limb, and digit abnormalities[0m[1;31m)[0m[31m were observed in rats, rabbits, and mice at doses as low as [0m[1;31m100[0m[31m, [0m[1;31m75[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg, respectively. [0m[1;31m8.2[0m[31m Lactation Risk Summary Phenytoin is secreted in human [0m
[31mmilk. The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for Phenytoin Sodium Injection and any potential adverse effects on the [0m
[31mbreastfed infant from Phenytoin Sodium Injection or from the underlying maternal condition. [0m[1;31m8[0m[31m. PHENYTOIN: use_in_specific_populations: [0m[1;31m4[0m[31m Pediatric Use A loading dose of [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m mg/kg of Phenytoin [0m
[31mSodium Injection intravenously will usually produce serum concentrations of phenytoin within the generally accepted serum total concentrations between [0m[1;31m10[0m[31m and [0m[1;31m20[0m[31m mcg/mL [0m[1;31m([0m[31munbound phenytoin [0m
[31mconcentrations of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mcg/mL[0m[1;31m)[0m[31m. Because of the increased risk of adverse cardiovascular reactions associated with rapid administration Phenytoin Sodium Injection should be injected slowly [0m
[31mintravenously at a rate not exceeding [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min or [0m[1;31m50[0m[31m mg per minute, whichever is slower [0m[31m. [0m[1;31m8.5[0m[31m Geriatric Use Phenytoin clearance tends to decrease with increasing age [0m[31m . Lower or less frequent [0m
[31mdosing may be required [0m[31m. [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: drug_interactions_table: oniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" [0m
[31mBotrule Toprule Lrule Rrule"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Drugs that may decrease phenytoin serum levels<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Antineoplastic agents usually [0m
[31min combination<[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Antiviral [0m
[31magents<[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Fosamprenavir, nelfinavir, rit PHENYTOIN: drug_interactions_table: onavir<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule [0m
[31mRrule"[0m[31m>Antiepileptic drugs<[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Carbamazepine, vigabatrin<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Other<[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule [0m
[31mToprule Lrule Rrule"[0m[31m><paragraph>Chronic alcohol abuse, diazepam, diazoxide, folic acid, reserpine, rifampin, St. PHENYTOIN: drug_interactions_table: John&#x2019;s wort<sup>b<[0m[31m/[0m[31msup[0m[31m>, [0m
[31mtheophylline<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Drugs that may either increase or decrease phenytoin [0m
[31mserum levels<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Antiepileptic drugs<[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m>Phenobarbital, valproate sodium, [0m
[31mvalproic acid<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: openfda: spl_id         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: warnings_and_cautions: Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or central vein through[0m
[31ma large-gauge catheter. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium Injection should then[0m
[31mbe followed by a flush of sterile saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium Injection administration [0m
[31mmay cause pain, necrosis, and abscess formation at the injection site [0m[31m . [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m9[0m[31m Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin[0m
[31mis increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m5.10[0m[31m [0m
[31mExacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this [0m
[31mdisease. [0m[1;31m5.11[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks [0m
[31mfor congenital malformations and other adverse developmental outcomes [0m[31m . PHENYTOIN: warnings_and_cautions: Increased frequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac defects[0m[1;31m)[0m[31m, [0m
[31mand abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive [0m
[31mdeficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases [0m
[31mof malignancies, including neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to [0m
[31mphenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. [0m[1;31m5.12[0m[31m Hyperglycemia Hyperglycemia, resulting[0m
[31mfrom the drug's inhibitory effect on insulin release, has been reported. PHENYTOIN: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic patients. [0m[1;31m5.13[0m[31m Serum Phenytoin [0m
[31mLevels Above Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as [0m[31m"delirium"[0m[31m, [0m[31m"psychosis"[0m[31m, or [0m[31m"encephalopathy"[0m[31m, or rarely [0m
[31mirreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction of phenytoin therapy is [0m
[31mindicated if serum levels are excessive; if symptoms persist, termination is recommended.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION W ithdrawal of Antiepileptic Drugs Advise patients not to discontinue use of phenytoin without consulting with their [0m
[31mhealthcare provider. Phenytoin should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus [0m[31m . P otential Signs of Drug Reaction with [0m
[31mEosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m and Other Systemic R eac tions Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic [0m
[31mreactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and petechial or purpuric hemorrhage, and[0m
[31min the case of liver reactions, anorexia, nausea/vomiting, or jaundice. PHENYTOIN: information_for_patients: Advise the patient that, because these signs and symptoms may signal a serious reaction, [0m
[31mthat they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use [0m[31m . [0m
[31mEffects of Alcohol Use and Other Drugs and Over-the-Counter Drug Interactions Caution patients against the use of other drugs or alcoholic beverages without first seeking their physicianâ€™s advice [0m[31m . [0m
[31mInform patients that certain over-the-counter medications [0m[1;31m([0m[31me.g., cimetidine and omeprazole[0m[1;31m)[0m[31m, vitamins [0m[1;31m([0m[31me.g., folic acid[0m[1;31m)[0m[31m, and herbal supplements [0m[1;31m([0m[31me.g., St. PHENYTOIN: information_for_patients: Johnâ€™s [0m
[31mwort[0m[1;31m)[0m[31m can alter their phenytoin levels. Hyperglycemia Advise patients that phenytoin may cause an increase in blood glucose levels [0m[31m . Gingival Hyperplasia Advise patients of the importance of good [0m
[31mdental hygiene in order to minimize the development of gingival hyperplasia and its complications. Neurologic Effects Counsel patients that phenytoin may cause dizziness, gait disturbance, decreased [0m
[31mcoordination and somnolence. Advise patients taking phenytoin not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects [0m
[31massociated with phenytoin. PHENYTOIN: information_for_patients: Use in Pregnancy Inform pregnant women and women of childbearing potential that use of phenytoin during pregnancy can cause fetal harm, [0m
[31mincluding an increased risk for cleft lip and/or cleft palate [0m[1;31m([0m[31moral clefts[0m[1;31m)[0m[31m, cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding [0m
[31mmicrocephaly[0m[1;31m)[0m[31m, and cognitive deficits. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who [0m
[31mare not planning a pregnancy to use effective contraception while using phenytoin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy [0m[31m. Instruct patients to notify[0m
[31mtheir physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy [0m[31m . PHENYTOIN: [0m
[31minformation_for_patients: Encourage patients to enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry if they become pregnant. This registry is collecting information about the [0m
[31msafety of antiepileptic drugs during pregnancy [0m[31m . Manufactured by: Hikma Pharmaceuticals USA Inc.         [0m
[31mSOURCE:PHENYTOIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Phenytoin may increase the risk of bleeding in newborns exposed to the drug in utero. This is due to a potentially life-threatening bleeding disorder related to decreased levels of vitamin [0m
[32mK-dependent clotting factors. This condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth.[0m

[32mSOURCE: PHENYTOIN label[0m
[32mEXTRACT_START_END: Fetal/Neonatal adverse reactions[0m[32m...[0m[32mafter birth.[0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Phenytoin may increase the risk of bleeding in newborns exposed to the [0m
[34mdrug in utero. This is due to a potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors. This condition can be prevented with vitamin K [0m
[34madministration to the mother before delivery and to the neonate after birth.[0m

[34mSOURCE: PHENYTOIN label[0m
[34mEXTRACT_START_END: Fetal/Neonatal adverse reactions[0m[34m...[0m[34mafter birth.[0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether PHENYTOIN increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Phenytoin may increase the risk of bleeding in newborns exposed to the drug in utero due to a potentially life-threatening bleeding disorder related to decreased [0m
[32mlevels of vitamin K-dependent clotting factors. This condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Phenytoin may increase the risk of bleeding in newborns who were exposed to the drug in utero. This is associated with a bleeding disorder due to decreased levels of vitamin K-dependent[0m
[32mclotting factors. The risk can be mitigated by administering vitamin K to the mother before delivery and to the newborn after birth."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether PHENYTOIN increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Phenytoin may increase the risk of bleeding in newborns exposed to the drug in utero due to a potentially life-threatening bleeding disorder related to decreased [0m
[34mlevels of vitamin K-dependent clotting factors. This condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Phenytoin may increase the risk of bleeding in newborns who were exposed to the drug in utero. This is associated with a bleeding disorder due to decreased levels of vitamin K-dependent[0m
[34mclotting factors. The risk can be mitigated by administering vitamin K to the mother before delivery and to the newborn after birth."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether PHENYTOIN increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that Phenytoin may increase the risk of bleeding in newborns exposed to the drug in utero due to a potentially life-threatening bleeding disorder related to decreased levels of[0m
[31mvitamin K-dependent clotting factors. This condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth.[0m
[31m        -----[0m
[31m        Final answer: Phenytoin may increase the risk of bleeding in newborns who were exposed to the drug in utero. This is associated with a bleeding disorder due to decreased levels of vitamin [0m
[31mK-dependent clotting factors. The risk can be mitigated by administering vitamin K to the mother before delivery and to the newborn after birth.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mPhenytoin may increase the risk of bleeding in newborns who were exposed to the drug in utero. This is associated with a bleeding disorder due to decreased levels of vitamin K-dependent clotting [0m
[32mfactors. The risk can be mitigated by administering vitamin K to the mother before delivery and to the newborn after birth.[0m
